Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28237732 | 1.00 | CYP1A2 (0.71) | CYP1A2ALDH1A1CHRM5L3MBTL1PPARG | |
| SCHEMBL28238797 | 1.00 | CYP1A2 (0.71) | CYP1A2ALDH1A1CHRM5L3MBTL1PPARG | |
| SCHEMBL664978 | 0.98 | CYP1A2 (0.69) | CYP1A2ALDH1A1CHRM5L3MBTL1PPARG | |
| SCHEMBL6662416 | 0.98 | CYP1A2 (0.69) | CYP1A2ALDH1A1CHRM5L3MBTL1PPARG | |
| SCHEMBL28296028 | 0.98 | CYP1A2 (0.69) | CYP1A2ALDH1A1CHRM5L3MBTL1PPARG | |
| SCHEMBL9136471 | 0.98 | CYP1A2 (0.69) | CYP1A2ALDH1A1CHRM5L3MBTL1PPARG | |
| SCHEMBL5105796 | 0.94 | CYP1A2 (0.62) | CYP1A2ALDH1A1CHRM5L3MBTL1PPARG | |
| SCHEMBL5988542 | 0.94 | CYP1A2 (0.62) | CYP1A2ALDH1A1CHRM5L3MBTL1PPARG | |
| SCHEMBL18263291 | 0.88 | — | — | |
| SCHEMBL12641503 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111393393-B | Preparation method of racemic beta-aryl-gamma-butyrolactone compound | 山东省医学科学院药物研究所（山东省抗衰老研究中心、山东省新技术制药研究所） | 2021-06-15 | — | — | CN | claimed |
| CN-111393393-A | Preparation method of racemization β -aryl-gamma-butyrolactone compound | 山东省医学科学院药物研究所（山东省抗衰老研究中心、山东省新技术制药研究所） | 2020-07-10 | — | — | CN | claimed |
| CN-109832623-A | A kind of nutrition fermented food | 臻味之(烟台)食品科技有限公司 | 2019-06-04 | — | — | CN | claimed |
| US-20220363632-A1 | Compounds Useful for Treating Liver Diseases | ABIONYX PHARMA SA (FR) | 2022-11-17 | — | — | US | disclosed |
| CN-111393393-B | Preparation method of racemic beta-aryl-gamma-butyrolactone compound | 山东省医学科学院药物研究所（山东省抗衰老研究中心、山东省新技术制药研究所） | 2021-06-15 | — | — | CN | disclosed |
| CN-111393393-B | Preparation method of racemic beta-aryl-gamma-butyrolactone compound | 山东省医学科学院药物研究所（山东省抗衰老研究中心、山东省新技术制药研究所） | 2021-06-15 | — | — | CN | disclosed |
| CN-111393393-B | Preparation method of racemic beta-aryl-gamma-butyrolactone compound | 山东省医学科学院药物研究所（山东省抗衰老研究中心、山东省新技术制药研究所） | 2021-06-15 | — | — | CN | disclosed |
| CN-111393393-A | Preparation method of racemization β -aryl-gamma-butyrolactone compound | 山东省医学科学院药物研究所（山东省抗衰老研究中心、山东省新技术制药研究所） | 2020-07-10 | — | — | CN | disclosed |
| CN-111393393-A | Preparation method of racemization β -aryl-gamma-butyrolactone compound | 山东省医学科学院药物研究所（山东省抗衰老研究中心、山东省新技术制药研究所） | 2020-07-10 | — | — | CN | disclosed |
| CN-111393393-A | Preparation method of racemization β -aryl-gamma-butyrolactone compound | 山东省医学科学院药物研究所（山东省抗衰老研究中心、山东省新技术制药研究所） | 2020-07-10 | — | — | CN | disclosed |
| CN-109832623-A | A kind of nutrition fermented food | 臻味之(烟台)食品科技有限公司 | 2019-06-04 | — | — | CN | disclosed |
| EP-0863890-A1 | 5-AMIDOMETHYL ALPHA, BETHA-SATURATED AND -UNSATURATED 3-ARYL BUTYROLACTONE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1998-09-16 | — | — | EP | disclosed |
| US-5708169-A | BACTERICIDES FOR TREATMENT OF GRAM POSITIVE INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| US-5708169-A | BACTERICIDES FOR TREATMENT OF GRAM POSITIVE INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| WO-1997010235-A1 | 5-AMIDOMETHYL α, β-SATURATED AND -UNSATURATED 3-ARYL BUTYROLACTONE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1997-03-20 | — | — | WO | disclosed |
| EP-0139206-B1 | GAMMA-BUTYROLACTONE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND IMMUNOMODULATING COMPOSITIONS CONTAINING THE SAME AS ACTIVE INGREDIENTS | MITSUBISHI KASEI CORPORATION (JP) | 1988-07-20 | — | — | EP | disclosed |
| US-4613613-A | ANTIARTHRITIC AGENTS | MITSUBISHI YUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-09-23 | — | — | US | disclosed |
| EP-0139206-A1 | Gamma-Butyrolactone derivatives, process for preparing the same and immunomodulating compositions containing the same as active ingredients | MITSUBISHI KASEI CORPORATION (JP) | 1985-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363632-A1 | Compounds Useful for Treating Liver Diseases | SLC10A1, FABP1, CPT1A | CYP1A2 227/4885ALDH1A1 103/4885CHRM5 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.